Stemgent
The development and commercialization of therapeutics and cellular technologies derived from the placenta.
Launch date
Employees
Market cap
-
Enterprise valuation
€41—62m (Dealroom.co estimates Aug 2012.)
Cambridge Massachusetts (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
$6.5m | Series A | ||
$14.0m | Series B | ||
$2.7m | Debt | ||
N/A | $5.6m | Early VC | |
N/A | $750k | Debt | |
$10.6m | Series B | ||
N/A | $580k | Debt | |
N/A | $6.3m | Early VC | |
N/A | $11.3m | Late VC | |
N/A | N/A | IPO | |
Total Funding | €49.4m |
Recent News about Stemgent
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.